IP Library › Granted Patent US 9,463,195
Granted Patent B2
US 9,463,195 · App. 12/519,058 · Granted Oct 11, 2016

Dissolution of amyloid fibrils by flavonoids and other compounds

Inventors: David S. Eisenberg (Los Angeles, CA); Melinda Balbirnie (Santa Monica, CA)
Assignee: The Regents of the University of California
A61K31/65A61M1/30A61M1/3486
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,463,195
App. No.
12/519,058
Granted
Oct 11, 2016
Kind
B2
Abstract

Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a β-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the β-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of an animal. It also relates to methods for determining which compounds are effective at disrupting amyloid fibrils in a medium.

Claims (16)

1. A dialysis system comprising an upstream blood side, an artificial kidney, and a downstream blood side, and benserazide hydrochloride, stictic acid, haemmatommic acid, meclocycline sulfosalicylate, dobutamine hydrochloride, apomorphine hydrochloride or primaquine diphosphate.

2. The dialysis system of claim 1 , wherein the system comprises benserazide hydrochloride.

3. The dialysis system of claim 1 , wherein the system comprises stictic acid.

4. The dialysis system of claim 1 , wherein the system comprises haemmatommic acid.

5. The dialysis system of claim 1 , wherein the system comprises meclocycline sulfosalicylate.

6. The dialysis system of claim 1 , wherein the system comprises dobutamine hydrochloride.

7. The dialysis system of claim 1 , wherein the system comprises apomorphine hydrochloride.

8. The dialysis system of claim 1 , wherein the system comprises primaquine diphosphate.

9. A method for treating dialysis-related amyloidosis in a subject comprising combining blood of the subject with a β-2 microglobulin fibril disrupting compound selected from the group consisting of one or more of benserazide hydrochloride, stictic acid, haemmatommic acid, meclocycline sulfosalicylate, dobutamine hydrochloride, apomorphine hydrochloride, and primaquine diphosphate, wherein the β-2 microglobulin fibril disrupting compound is combined ex vivo with the blood during dialysis treatment of the subject.

10. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises benserazide hydrochloride.

11. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises stictic acid.

12. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises haemmatommic acid.

13. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises meclocycline sulfosalicylate.

14. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises dobutamine hydrochloride.

15. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises apomorphine hydrochloride.

16. The method of claim 9 , wherein the β-2 microglobulin fibril disrupting compound comprises primaquine diphosphate.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 17, 2010
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024845/0647 →
CONFIRMATORY LICENSE Recorded Jul 7, 2009
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022919/0433 →
Continuity (2)
Provisional Application 60874950 · Dec 15, 2006
Related Publication 20100048510A1 · Feb 25, 2010